I think he is referring to starting trials for things like
I think he is referring to starting trials for things like MS and other BBB indications.
Given that there is a waiting list of VERY motivated people to join a Long Haulers trial I think its an easy decision.
Even though it is a phase 2, it will be small number and should enroll very quickly.
We could very well see completion of (3) phase 3 trials within a close proximity of each other. I think perhaps end of year, or January?
If we were to see (3) phase three trials achieve stat significance, I cannot imagine a world in which the FDA did not approve us.
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...
Continue Reading
They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...
Continue Reading
A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...
Continue Reading
Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...
Continue Reading
Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...
Continue Reading
Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...
Continue Reading
AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...
Continue Reading
Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...
Continue Reading
They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...
Continue Reading
A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...
Continue Reading
Top 5 Most Recently Viewed Articles
JPMorgan Chase & Co. launched an impressive $8 billion sale of U.S. investment-grade corporate bonds back in 2024, right after dropping its earnings report. Desks were buzzing as the move signaled that major Wall Street players were getting back into the bond game with real vigor. Investor Enthusiasm: A Bond Bonanza The offering was broken down into four parts, showing...
Continue Reading
DocuSign's Market Position Strengthens with New Inclusion Shares in DocuSign (NASDAQ: DOCU) have seen an impressive rise of over 5% in premarket trading recently. This increase comes on the heels of an announcement from S&P Dow Jones Indices regarding the company's inclusion in the S&P MidCap 400 index, marking a significant milestone for the e-signature service provider....
Continue Reading
Understanding the Neumora Therapeutics Class Action Lawsuit Investors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) have a significant opportunity to participate in a class action lawsuit following allegations of securities fraud. This lawsuit has stemmed from the common stock offerings related to the company, which took place during its public fundraising efforts. As a...
Continue Reading
Overview of the Thermoplastic Elastomers Market The global market for Thermoplastic Elastomers (TPE) is on track to reach USD 44.29 billion by the end of the forecast period. With a compound annual growth rate (CAGR) of 5.10% anticipated from 2024 to 2031, this segment is gaining attention due to its diverse applications and innovative characteristics. Growth Drivers in...
Continue Reading
Acadia Healthcare got eyes on it as Jefferies slapped a Buy rating back in 2024 and kept the price target at $105. Traders were buzzing about the resilience factor; this firm believes Acadia can weather the storm of recent legal headaches. Sure, the legal chatter is loud, but Jefferies hinted that fears might be overblown. They pointed out how settlements usually don’t...
Continue Reading